Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 -- Adlai Nortye Ltd. , a clinical-stage biotechnology company focused on the development of innovative cancer therapies,...

Related Keywords

United States ,China ,Singapore ,Hangzhou ,Zhejiang ,New Jersey ,America ,Adlai Nortye ,Lars Birgerson ,Amanda Kong ,Charles Zhou ,Company Or Adlai Nortye ,Adlai Nortye Ltd ,Exchange Commission ,Novartis ,Nasdaq ,Patient Enrollment ,Global Phase ,North America ,Chief Medical Officer ,Securities Litigation Reform Act ,Markets ,